Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplementary Material] Other (Supplementary Material)
699kB

Item Type:Article
Title:Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Creators Name:Döhner, H., Dolnik, A., Tang, L., Seymour, J.F., Minden, M.D., Stone, R.M., Del Castillo, T.B., Al-Ali, H.K., Santini, V., Vyas, P., Beach, C L., MacBeth, K.J., Skikne, B.S., Songer, S., Tu, N., Bullinger, L. and Dombret, H.
Abstract:Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyotype (HR 0.71 [95%CI 0.51-0.99]; P = 0.046). Azacitidine-treated patients with -5/5q-, -7/7q-, or 17p abnormalities, or with monosomal or complex karyotypes, had a 31-46% reduced risk of death vs CCR. The most frequent gene mutations were DNMT3A (27%), TET2 (25%), IDH2 (23% [R140, 15%; R172, 8%]), and TP53 (21%). Compared with wild-type, OS was significantly reduced among CCR-treated patients with TP53 or NRAS mutations and azacitidine-treated patients with FLT3 or TET2 mutations. Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics, particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes. The influence of gene mutations in azacitidine-treated patients warrants further study.
Keywords:Acute Myeloid Leukemia, Antineoplastic Antimetabolites, Azacitidine, Cytarabine, Cytogenetics, Karyotype, Mutation
Source:Leukemia
ISSN:1476-5551
Publisher:Nature Publishing Group
Volume:32
Number:12
Page Range:2546-2557
Date:December 2018
Official Publication:https://doi.org/10.1038/s41375-018-0257-z
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library